
Sign up to save your podcasts
Or
In this week's episode we'll learn about the updated phase 3 results on fixed-dose venetoclax plus obinutuzumab in previously untreated CLL. Then, we'll hear about dual epi-immunotherapy in classical Hodgkin lymphoma. Finally we'll explore redefining risk of treatment failure in CML.
Featured Articles:
4.1
4848 ratings
In this week's episode we'll learn about the updated phase 3 results on fixed-dose venetoclax plus obinutuzumab in previously untreated CLL. Then, we'll hear about dual epi-immunotherapy in classical Hodgkin lymphoma. Finally we'll explore redefining risk of treatment failure in CML.
Featured Articles:
129 Listeners
71 Listeners
319 Listeners
26 Listeners
489 Listeners
273 Listeners
2 Listeners
186 Listeners
362 Listeners
3 Listeners
2 Listeners
29 Listeners
165 Listeners
48 Listeners
1 Listeners